Core Viewpoint - The announcement by the company regarding the promising efficacy results of ASC47 in combination with Tirzepatide for obesity treatment in diet-induced obesity (DIO) mouse models highlights a significant advancement in obesity therapeutics [1] Group 1: Drug Efficacy - The combination of low-dose ASC47 with Tirzepatide resulted in an 87% greater weight reduction compared to Tirzepatide alone in DIO mouse models [1] - ASC47 combined with Semaglutide showed a 55% greater weight reduction compared to Semaglutide alone, indicating that ASC47 enhances the efficacy of existing obesity treatments [1] - The treatment with low-dose ASC47 and Tirzepatide restored the body composition of obese mice to levels comparable to healthy non-obese mice [1] Group 2: Muscle Mass Preservation - At the end of the treatment, the total muscle mass percentage of obese mice treated with low-dose ASC47 and Tirzepatide (60.4%) was similar to that of healthy non-obese mice (62.0%), suggesting that the treatment preserves muscle mass while promoting weight loss [1]
歌礼制药：ASC47在临床前模型中显示与替尔泊肽联用的疗效胜过与司美格鲁肽联用